As part of an international network of RA patient organizations, Arthritis Consumer Experts invites you to participate in a global survey of RA patients to examine the diagnosis, treatment and care they receive for their RA. The goal of this survey is to understand, from the patient experience and perspective, how current “models of care” for rheumatoid arthritis compare between countries.
Your experience and perspective matter
As a person living with RA, sharing your experiences about the care you receive is vitally important. With your help, we can meet the study goals and develop education and information programs to improve patients’ understanding about RA models of care to enable the best treatment outcomes possible in Canada.
How you can participate
If you agree to participate, you will be asked to answer a survey questionnaire, which should take approximately 10 minutes to complete. All the information gathered during the survey will be combined to protect your privacy and anonymity.
To be eligible to participate in this survey, you must:
Be 18 years of age or older
Receive health care in Canada
Have access to the internet
Thank you for considering our request to participate in this survey. Your participation will help you and other people living with RA in your country know more about the health care they should be receiving.
BC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis
Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. Continue reading →
Raynaud’s phenomenon is a condition in which there is an exaggerated blood vessel tightening in response to cold or emotional stress, restricting blood flow to certain areas of the body – most often the fingers, but sometimes the toes, ears, or the end of the nose.
The exaggerated vascular response (tightening) in Raynaud’s phenomenon is called vasospasm, which often occur in response to cold or emotional stress. With vasospasm, the fingers turn white and cold then blue with dilated veins followed by relaxation of the vessel and normal blood flow causing a red ‘flushing’
According to a recent article published in The New England Journal of Medicine, Raynaud’s affects approximately 3 to 5 percent of the population – women are more often affected than men. Raynaud’s phenomenon occurs in two forms – primary and secondary. Primary is the most common and has no underlying cause. Secondary is when Raynaud’s phenomenon occurs in combination with another autoimmune disease like scleroderma, rheumatoid arthritis, Sjogren’s syndrome or systemic lupus erythematous. The article also states that people who work with certain chemicals, like vinyl chloride, or vibrating tools like a jackhammer are also susceptible to secondary Raynaud’s. Continue reading →
Do you have rheumatoid arthritis, ankylosing spondylitis or polyarticular juvenile idiopathic arthritis or care for someone who does? We need your valuable input.
Health Canada defines biosimilars (sometimes referred to as subsequent entry biologics or SEBs) as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Enbrel®).
Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. Biosimilars are not identical to their originator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, biosimilars may have unique efficacy, immunogenicity, and safety profiles that are different from their originator.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar etanercept for the treatment of rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis. The originator biologic, or reference product, is etanercept (Enbrel®). Continue reading →
MedPage Today interviewed specialists in rheumatology in the United States about the advances in rheumatology in 2016. Below are the five most common advances mentioned.
1. Tocilizumab (Actemra) for the treatment of giant cell arteritis
Giant cell arteritis affects over 200,000 people in the United States. Research data from an international clinical trial showed that after a year of treatment, 56% of the 250 study participants given tocilizumab weekly plus prednisone were in sustained remission, compared with just 14% of those given placebo alone (P<0.0001).
At the annual meeting of the American College of Rheumatology (ACR), Dr. John H. Stone of Harvard University at Boston noted: “There is something new in giant cell arteritis at last, and the era of unending glucocorticoid treatment with no viable alternative is over.” Continue reading →
RA Matters is an international project aiming to explore what matters most to people living with RA. Using online crowdsourcing to invite participants, RA Matters asks questions about relationships, activities, work and aspirations, in order to reveal the most important aspects of day-to-day life. RA Matters aims to elevate a global conversation that sheds light on what those with RA really want and – ultimately – help them live the best life possible.